MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.jrn.2011.10.007

Медицинская библиотека · Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2012

Therapy of hyperhomocysteinemia in hemodialysis patients: effects of folates and N-acetylcysteine.

Perna Alessandra F, Violetti Eleonora, Lanza Diana, Sepe Immacolata, Bellinghieri Guido, Savica Vincenzo, Santoro Domenico, Satta Ersilia, Cirillo Giovanni, Lupo Antonio, Abaterusso Cataldo, Raiola Ilaria, Raiola Paolino, Coppola Salvatore, Di Iorio Biagio, Tirino Giuseppina, Cirillo Massimo, Ingrosso Diego, De Santo Natale G

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

Uremia represents a state where hyperhomocysteinemia is resistant to folate therapy, thus undermining intervention trials' efficacy. N-acetylcysteine (NAC), an antioxidant, in addition to folates (5-methyltetrahydrofolate, MTHF), was tested in a population of hemodialysis patients.

DESIGN

The study is an open, parallel, intervention study.

SETTING

Ambulatory chronic hemodialysis patients.

SUBJECTS: Clinically stable chronic hemodialysis patients, on hemodialysis since more than 3 months, undergoing a folate washout. Control group on standard therapy (n = 50).

INTERVENTION: One group was treated with intravenous MTHF (MTHF group, n = 48). A second group was represented by patients treated with MTHF, and, during the course of 10 hemodialysis sessions, NAC was administered intravenous (MTHF + NAC group, n = 47).

MAIN OUTCOME MEASURE: Plasma homocysteine measured before and after dialysis at the first and the last treatment.

RESULTS

At the end of the study, there was a significant decrease in predialysis plasma homocysteine levels in the MTHF group and MTHF + NAC group, compared with the control group, but no significant difference between the MTHF group and MTHF + NAC group. A significant decrease in postdialysis plasma homocysteine levels in MTHF + NAC group (10.27 ± 0.94 μmol/L, 95% confidence interval: 8.37-12.17) compared with the MTHF group (16.23 ± 0.83, 95% confidence interval: 14.55-17.90) was present. In the MTHF + NAC group, 64% of patients reached a postdialysis homocysteine level <12 μmol/L, compared with 19% in the MTHF group and 16% in the control group.

CONCLUSIONS

NAC therapy induces a significant additional decrease in homocysteine removal during dialysis. The advantage is limited to the time of administration.

Для цитирования: Perna Alessandra F, Violetti Eleonora, Lanza Diana, Sepe Immacolata, Bellinghieri Guido, Savica Vincenzo, Santoro Domenico, Satta Ersilia, Cirillo Giovanni, Lupo Antonio, Abaterusso Cataldo, Raiola Ilaria, Raiola Paolino, Coppola Salvatore, Di Iorio Biagio, Tirino Giuseppina, Cirillo Massimo, Ingrosso Diego, De Santo Natale G. Therapy of hyperhomocysteinemia in hemodialysis patients: effects of folates and N-acetylcysteine.. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2012. DOI: 10.1053/j.jrn.2011.10.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.